Prostate cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ADT, Abiraterone, Apalutamide Variant #01 Partial | — | R 574 768 | — | — | — | ~1 | ~R 574 768 indirect | — |
Leuprolide monotherapy Variant #01 | — | R 253 833 | 90d | — | — | 2 | R 507 665 PFS proxy | 2 |
Enzalutamide and Leuprolide Variant #01 | — | R 52 651 | 84d | — | — | 2 | R 105 301 PFS proxy | 1 |
Enzalutamide monotherapy Variant #01 | — | R 14 528 | 28d | 4.2 mo | 17.5 mo | 2 | R 29 057 PFS proxy | 13 |
ADT and Apalutamide Variant #01 Partial | — | R 1 206 | — | — | 73.9 mo | 1 | R 1 206 PFS proxy | 2 |
ADT Variant #01 Partial | — | — | — | — | 52.0 mo | 1 | — | 14 |
6 of 6 regimens shown